Hao Gu Zhenping Chen Jie Ma Jing Wang Rui Zhang Runhui Wu Tianyou Wang
10.1177/20587384211025934
Int J Immunopathol Pharmacol
2021 Jan-Dec;35:20587384211025934.
dnt prkcd variation treg autoimmune lymphoproliferative syndrome-type iii
CC BY-NC
https://pubmed.ncbi.nlm.nih.gov/34187243/
Autoimmune Lymphoproliferative Syndrome / drug therapy Immunosuppressive Agents / therapeutic use Protein Kinase C-delta / genetics Sirolimus / therapeutic use
Autoimmune Lymphoproliferative Syndrome / drug therapy Immunosuppressive Agents / therapeutic use Protein Kinase C-delta / genetics Sirolimus / therapeutic use Case Reports Autoimmune Lymphoproliferative Syndrome / genetics Child Genetic Variation Homozygote Humans Male Pedigree Treatment Outcome Immunosuppressive Agents PRKCD protein, human Protein Kinase C-delta Sirolimus
PMC8252363
34187243
Sirolimus is effective in autoimmune lymphoproliferative syndrome-type III: A pedigree case report with homozygous variation PRKCD
2021